Axon Enterprise, Inc (NASDAQ:AXON) Shares Sold by JSF Financial LLC

Key Points

• JSF Financial LLC has reduced its stake in Axon Enterprise by 38.6%, selling 1,119 shares, and now holds 1,780 shares valued at approximately $936,000.
• Multiple institutional investors, including Capital World Investors and Alliancebernstein L.P., have significantly increased their stakes in Axon Enterprise, with some growing by more than 273% in the last quarter.
• A recent earnings report showed Axon Enterprise exceeding analysts' expectations with a 31.3% revenue increase year-over-year, reporting earnings of $1.41 per share against expectations of $1.34.

JSF Financial LLC lowered its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 38.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,780 shares of the biotechnology company's stock after selling 1,119 shares during the period. JSF Financial LLC's holdings in Axon Enterprise were worth $936,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in AXON. Geode Capital Management LLC increased its position in Axon Enterprise by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company's stock worth $1,095,542,000 after purchasing an additional 65,097 shares during the period. Capital World Investors increased its position in Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after purchasing an additional 841,772 shares during the period. Alliancebernstein L.P. increased its position in Axon Enterprise by 273.8% during the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock worth $659,128,000 after purchasing an additional 812,337 shares during the period. GAMMA Investing LLC increased its position in Axon Enterprise by 58,725.5% during the 1st quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock worth $402,210,000 after purchasing an additional 763,431 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Axon Enterprise by 19.8% during the 4th quarter. Northern Trust Corp now owns 716,926 shares of the biotechnology company's stock worth $426,083,000 after acquiring an additional 118,469 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.

Insider Buying and Selling at Axon Enterprise

In other news, CAO Jennifer H. Mak sold 75 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $771.81, for a total transaction of $57,885.75. Following the completion of the sale, the chief accounting officer directly owned 15,240 shares in the company, valued at $11,762,384.40. This represents a 0.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Michael Garnreiter sold 5,913 shares of the stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $760.00, for a total value of $4,493,880.00. Following the completion of the sale, the director owned 17,740 shares of the company's stock, valued at approximately $13,482,400. This represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,642 shares of company stock worth $25,090,528. 4.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

AXON has been the topic of several research analyst reports. JMP Securities boosted their price target on Axon Enterprise from $725.00 to $825.00 and gave the stock a "market outperform" rating in a research note on Tuesday, July 22nd. UBS Group initiated coverage on Axon Enterprise in a research note on Wednesday, July 16th. They set a "neutral" rating and a $820.00 price target on the stock. Bank of America boosted their price target on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research note on Wednesday, June 4th. JPMorgan Chase & Co. boosted their price target on Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a research note on Thursday, July 17th. Finally, Barclays upped their target price on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $772.08.

Axon Enterprise Trading Down 2.0%

Shares of AXON stock traded down $15.32 on Friday, reaching $740.17. 278,467 shares of the stock were exchanged, compared to its average volume of 694,946. The stock has a market cap of $57.62 billion, a P/E ratio of 178.79, a price-to-earnings-growth ratio of 83.44 and a beta of 1.29. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. The firm has a 50 day moving average of $764.32 and a two-hundred day moving average of $655.08. Axon Enterprise, Inc has a 1-year low of $279.02 and a 1-year high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The business's revenue for the quarter was up 31.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.15 EPS. On average, research analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.